GlassScriptPhysician profile
Lauren Broadway
NPI 1811263643
$6,251.59
in general payments reported to CMS, 2019-2025
35 companies · $1,118 in 2025
The $1,118 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $256 · 2021: $447 · 2022: $1,417 · 2023: $710 · 2024: $1,286 · 2025: $1,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,939 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,938.68 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $840.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $699.23 | 2019-2025 | Prolia, Otezla, Repatha |
| Lilly USA, LLC | $649.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $560.30 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $512.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $406.56 | 2019-2025 | |
| Astellas Pharma US INC | $286.75 | 2019-2024 | Myrbetriq, Veozah |
| Boston Scientific Corporation | $276.41 | 2019-2024 | Watchman Flx, Eluvia |
| Biohaven Pharmaceutical Holding Company LTD. | $272.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $186.21 | 2022-2024 | |
| Glaxosmithkline, LLC. | $182.37 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $171.28 | 2023-2024 | |
| Merit Medical Systems INC | $161.41 | 2024 | Endomaxx Stent and Delivery System |
| Allergan, INC. | $142.56 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $125.00 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $109.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $108.69 | 2019-2024 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $73.33 | 2022-2024 | Xarelto |
| Exact Sciences Corporation | $62.78 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $42.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.54 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.73 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $27.52 | 2024 | Auvelity |
| Sanofi-Aventis U.S. LLC | $24.86 | 2019 | |
| Phadia US INC. | $23.64 | 2024 | Immunocap |
| Philips North America LLC | $21.29 | 2024 | (Ck6) Holter |
| Sanofi Pasteur INC. | $20.21 | 2019 | |
| Abbott Laboratories | $18.54 | 2024 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $16.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.23 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.64 | 2019 | |
| Almatica Pharma LLC | $14.09 | 2022 | |
| Currax Pharmaceuticals LLC | $13.38 | 2024 | Contrave |
| Kowa Pharmaceuticals America, INC. | $13.20 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Broadway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.